FDA schedules panel review of Sanofi's Multaq in March

11/30/2008 | Bloomberg · Reuters

Sanofi-Aventis announced that an FDA advisory committee will meet March 18 to evaluate Multaq, a drug candidate for atrial fibrillation. The move delays the agency's decision on the medicine, which secured priority-review status in July. Multaq could generate more than $2 billion in yearly sales, some analysts said.

View Full Article in:

Bloomberg · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ